United States Food and Drug Administration (USFDA) has conducted an unannounced inspection at Caplin Point Laboratories’ subsidiary, Caplin Steriles’ injectable and ophthalmic manufacturing facility located at Gummidipoondi, Tamil Nadu. The inspection was conducted between August 13, 2026, and August 21, 2026.
At the end of the inspection, the company received Form 483 with 10 observations. The observations are procedural in nature and does not pertain to data integrity and none of them were repeat observations. The company is addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe.
Caplin Point Laboratories is the mid-sized company in India’s pharmaceutical sector to be engaged in the manufacture of APIs, finished formulations, research & development, clinical research, frontend generic presence in Latin America, brand marketing in Francophone Africa and an USFDA approved injectable facility.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1909.90 |
| Dr. Reddys Labs. | 1194.50 |
| Cipla | 1435.00 |
| Lupin | 2190.00 |
| Zydus Lifesciences | 1101.00 |
| View more.. | |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: